Literature DB >> 15362874

Substrate-dependent modulation of the mechanism of factor XIa inhibition.

Donna L Pedicord1, Dietmar Seiffert, Yuval Blat.   

Abstract

Factor XIa is a serine protease which participates in both the extrinsic and intrinsic pathways of blood coagulation. In this work we used active site directed inhibitors to study the mechanism of factor IX activation by factor XIa. To this end, we developed a new sensitive method for the detection of factor IXa based on its affinity to antithrombin III. Using this assay, we found that the peptidic inhibitors, leupeptin and aprotinin, exhibited similar potencies in inhibiting factor IX activation and the cleavage of a tripeptidic chromogenic substrate by factor XIa. As expected, leupeptin and aprotinin were competitive with respect to the tripeptidic chromogenic substrate. However, the inhibition of factor IX activation was best described by mixed-type inhibition with the affinity of leupeptin and aprotinin to the factor XIa-factor IX complex only approximately 10-fold lower than their affinity toward factor XIa. These results, consistent with previous factor XI domain analyses, suggest that the active site of factor XIa does not contribute significantly to the affinity of factor XIa toward factor IX. The competitive component of the inhibition of factor IX activation suggests that binding of factor IX to factor XIa heavy chain affects the interactions of leupeptin and aprotinin with the active site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362874     DOI: 10.1021/bi048964g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Coagulation procofactor activation by factor XIa.

Authors:  M F Whelihan; T Orfeo; M T Gissel; K G Mann
Journal:  J Thromb Haemost       Date:  2010-05-04       Impact factor: 5.824

2.  Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX.

Authors:  Taketoshi Ogawa; Ingrid M Verhamme; Mao-Fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2005-04-13       Impact factor: 5.157

Review 3.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

4.  Feedback activation of factor XI by thrombin does not occur in plasma.

Authors:  Donna L Pedicord; Dietmar Seiffert; Yuval Blat
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

5.  In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.

Authors:  Pancras C Wong; Mimi L Quan; Carol A Watson; Earl J Crain; Mark R Harpel; Alan R Rendina; Joseph M Luettgen; Ruth R Wexler; William A Schumacher; Dietmar A Seiffert
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

6.  In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2.

Authors:  Lucas N Alberca; Sara R Chuguransky; Cora L Álvarez; Alan Talevi; Emir Salas-Sarduy
Journal:  Front Chem       Date:  2019-08-06       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.